BLOOD, LYMPH AND RELATED CONDITIONS:@0.084848:0.038601:0.564720:0.038601:0.564720:0.019343:0.084848:0.019343:0.013500:0.010866:0.020438:0.020438:0.017498:0.006515:0.006515:0.008735:0.013923:0.021613:0.013923:0.016063:0.006515:0.017404:0.017404:0.017498:0.006515:0.014276:0.012606:0.010866:0.015466:0.010019:0.012606:0.017498:0.006515:0.019121:0.020438:0.017404:0.017498:0.005315:0.010019:0.005315:0.020438:0.017404:0.011712
106:@0.018436:0.038809:0.050045:0.038809:0.050045:0.019212:0.018436:0.019212:0.010536:0.010536:0.010536
HANDBOOK OF ONCOLOGY:@0.084848:0.970015:0.320957:0.970015:0.320957:0.956010:0.084848:0.956010:0.011682:0.012657:0.012657:0.012726:0.009818:0.014864:0.014864:0.010109:0.004738:0.014864:0.008296:0.004738:0.014864:0.012657:0.013906:0.014864:0.007902:0.014864:0.014915:0.010126
REFERENCES:@0.084242:0.093226:0.195079:0.093226:0.195079:0.077192:0.084242:0.077192:0.011161:0.010006:0.009236:0.010006:0.011161:0.010006:0.014239:0.015009:0.010006:0.010006
1. :@0.084242:0.109954:0.103194:0.109954:0.103194:0.095949:0.084242:0.095949:0.009479:0.004734:0.004738
 Rachet B, Maringe C, Nur U, :@0.120587:0.109954:0.375718:0.109954:0.375718:0.095949:0.120587:0.095949:0.000000:0.009869:0.011169:0.010553:0.009921:0.010605:0.005285:0.010964:0.009305:0.004225:0.010964:0.015206:0.011169:0.004635:0.002908:0.009921:0.010998:0.010605:0.010964:0.013393:0.004225:0.010964:0.012144:0.009886:0.004635:0.010964:0.010690:0.004225:0.004738
et al.:@0.381944:0.109954:0.427612:0.109954:0.427612:0.095949:0.381944:0.095949:0.010605:0.005285:0.010964:0.011169:0.002908:0.004738
 Pop-:@0.427099:0.109954:0.475197:0.109954:0.475197:0.095949:0.427099:0.095949:0.010964:0.009613:0.010690:0.011152:0.005679
ulation-based cancer survival trends in :@0.120589:0.124065:0.479863:0.124065:0.479863:0.110060:0.120589:0.110060:0.009886:0.002908:0.011169:0.005285:0.002908:0.010690:0.009921:0.005166:0.011152:0.011169:0.006123:0.010605:0.011203:0.018079:0.010553:0.011169:0.009921:0.010553:0.010605:0.004635:0.018079:0.006123:0.009886:0.004635:0.008963:0.002908:0.008963:0.011169:0.002908:0.018079:0.005285:0.004565:0.010605:0.009921:0.011203:0.006123:0.018079:0.002908:0.010432:0.004738
England  and  Wales  up to 2007: an  as-:@0.120589:0.138176:0.475149:0.138176:0.475149:0.124171:0.120589:0.124171:0.008655:0.009921:0.010998:0.002908:0.011169:0.009921:0.011203:0.004738:0.008184:0.011169:0.009921:0.011203:0.004738:0.008184:0.015055:0.011169:0.002908:0.010605:0.006123:0.004738:0.008184:0.009886:0.011152:0.012931:0.005285:0.010690:0.012931:0.008963:0.008963:0.008963:0.008963:0.004225:0.012931:0.011169:0.009921:0.004738:0.008184:0.011169:0.006123:0.005679
sessment of the NHS cancer plan for Eng-:@0.120589:0.152288:0.475180:0.152288:0.475180:0.138282:0.120589:0.138282:0.006123:0.010605:0.006123:0.006123:0.015531:0.010605:0.009921:0.005285:0.009082:0.010690:0.004858:0.009082:0.005285:0.009921:0.010605:0.009082:0.012144:0.011169:0.008005:0.009082:0.010553:0.011169:0.009921:0.010553:0.010605:0.004635:0.009082:0.011152:0.002908:0.011169:0.009921:0.009082:0.004858:0.010690:0.004635:0.009082:0.008655:0.009921:0.010998:0.005679
land. :@0.120589:0.166399:0.164753:0.166399:0.164753:0.152393:0.120589:0.152393:0.002908:0.011169:0.009921:0.011203:0.004225:0.004738
Lancet Oncol. :@0.180352:0.166399:0.312996:0.166399:0.312996:0.152393:0.180352:0.152393:0.007389:0.011169:0.009921:0.010553:0.010605:0.005285:0.020337:0.014351:0.009921:0.010553:0.010690:0.002908:0.004225:0.004738
2009;10(4) 351-369.  :@0.328595:0.166399:0.479883:0.166399:0.479883:0.152393:0.328595:0.152393:0.008963:0.008963:0.008963:0.008963:0.004225:0.008963:0.008963:0.005798:0.008963:0.006312:0.003780:0.008963:0.008963:0.008963:0.005166:0.008963:0.008963:0.008963:0.004736:0.000000:0.004738
::@0.407156:0.166399:0.411945:0.166399:0.411945:0.152146:0.407156:0.152146:0.004789
e-pub 2009/03/24; Doi: 10.1016/s1470-2045(09) :@0.120589:0.180510:0.479883:0.180510:0.479883:0.166504:0.120589:0.166504:0.010605:0.005166:0.011152:0.009886:0.011152:0.002880:0.008963:0.008963:0.008963:0.008963:0.006961:0.008963:0.008963:0.006961:0.008963:0.008963:0.004225:0.002880:0.012213:0.010690:0.002908:0.004225:0.002880:0.008963:0.008963:0.004225:0.008963:0.008963:0.008963:0.008963:0.006961:0.006123:0.008963:0.008963:0.008963:0.008963:0.005166:0.008963:0.008963:0.008963:0.008963:0.005798:0.008963:0.008963:0.006394:0.004738
70028-2.:@0.120589:0.194186:0.184269:0.194186:0.184269:0.180181:0.120589:0.180181:0.008963:0.008963:0.008963:0.008963:0.008963:0.005166:0.008963:0.004738
2. :@0.084242:0.207862:0.103194:0.207862:0.103194:0.193857:0.084242:0.193857:0.009476:0.004738:0.004738
 De Angelis R, Sant M, Coleman MP, :@0.120589:0.207862:0.429044:0.207862:0.429044:0.193857:0.120589:0.193857:0.000000:0.012726:0.011118:0.007064:0.012657:0.010434:0.011511:0.011118:0.003421:0.003421:0.006636:0.007064:0.010382:0.004738:0.007064:0.008518:0.011682:0.010434:0.005798:0.007064:0.015719:0.004738:0.007064:0.013906:0.011203:0.003421:0.011118:0.016044:0.011682:0.010434:0.007064:0.015719:0.008017:0.004738:0.004738
et al.:@0.431370:0.207862:0.475192:0.207862:0.475192:0.193857:0.431370:0.193857:0.011118:0.005798:0.007064:0.011682:0.003421:0.004738
 :@0.475192:0.207862:0.479930:0.207862:0.479930:0.193857:0.475192:0.193857:0.004738
Cancer survival  in Europe 1999-2007  by :@0.120589:0.221538:0.479890:0.221538:0.479890:0.207533:0.120589:0.207533:0.013906:0.011682:0.010434:0.011067:0.011118:0.005148:0.011340:0.006636:0.010399:0.005148:0.009476:0.003421:0.009476:0.011682:0.003421:0.004738:0.006616:0.003421:0.010434:0.011340:0.009168:0.010399:0.005078:0.011203:0.011665:0.011118:0.011340:0.009476:0.009476:0.009476:0.009489:0.005679:0.009476:0.009476:0.009476:0.009476:0.004738:0.006618:0.011665:0.009168:0.004738
country and age: results of EUROCARE-5 – :@0.120589:0.235214:0.479873:0.235214:0.479873:0.221209:0.120589:0.221209:0.011067:0.011203:0.010399:0.010434:0.005798:0.005148:0.009168:0.006217:0.011682:0.010434:0.011716:0.006226:0.011682:0.011511:0.011118:0.004738:0.006226:0.005078:0.011118:0.006636:0.010399:0.003421:0.005798:0.006636:0.006226:0.011203:0.005371:0.006226:0.009168:0.011203:0.010382:0.014864:0.013906:0.012657:0.010382:0.009168:0.005679:0.009476:0.006226:0.008552:0.004738
a population-based study. :@0.120589:0.248890:0.345748:0.248890:0.345748:0.234885:0.120589:0.234885:0.011682:0.005446:0.011665:0.011203:0.011665:0.010399:0.003421:0.011682:0.005798:0.003421:0.011203:0.010434:0.005679:0.011665:0.011682:0.006636:0.011118:0.011716:0.005446:0.006636:0.005798:0.010399:0.011716:0.009168:0.004738:0.004738
The Lancet On-:@0.346452:0.248890:0.475142:0.248890:0.475142:0.234885:0.346452:0.234885:0.007286:0.010434:0.011118:0.005437:0.007902:0.011682:0.010434:0.011067:0.011118:0.005798:0.005437:0.014864:0.010434:0.005679
cology. :@0.120589:0.262566:0.187638:0.262566:0.187638:0.248561:0.120589:0.248561:0.011067:0.011203:0.003421:0.011203:0.011511:0.009168:0.004738:0.004738
2014;15(1) 23-34.:@0.187621:0.262566:0.329245:0.262566:0.329245:0.248561:0.187621:0.248561:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.006312:0.009476:0.006312:0.009613:0.009476:0.009476:0.005679:0.009476:0.009476:0.004738
: :@0.271347:0.262566:0.280925:0.262566:0.280925:0.248314:0.271347:0.248314:0.004789:0.004789
3. :@0.084242:0.276242:0.103194:0.276242:0.103194:0.262237:0.084242:0.262237:0.009476:0.004738:0.004738
 Sant M, Allemani C, Tereanu C, :@0.120589:0.276242:0.389663:0.276242:0.389663:0.262237:0.120589:0.262237:0.000000:0.008518:0.011682:0.010434:0.005798:0.006335:0.015719:0.004738:0.006334:0.012657:0.003421:0.003421:0.011118:0.016044:0.011682:0.010434:0.003421:0.006346:0.013906:0.004738:0.006334:0.006448:0.011118:0.005077:0.011118:0.011682:0.010434:0.010399:0.006337:0.013906:0.004738:0.004738
et al.:@0.391249:0.276242:0.434340:0.276242:0.434340:0.262237:0.391249:0.262237:0.011118:0.005798:0.006334:0.011682:0.003421:0.004738
 Inci-:@0.434340:0.276242:0.475142:0.276242:0.475142:0.262237:0.434340:0.262237:0.006337:0.003866:0.010434:0.011067:0.003421:0.005679
dence of hematologic malignancies in Eu-:@0.120589:0.289918:0.475145:0.289918:0.475145:0.275913:0.120589:0.275913:0.011716:0.011118:0.010434:0.011067:0.011118:0.005131:0.011203:0.005371:0.005131:0.010434:0.011118:0.016044:0.011682:0.005798:0.011203:0.003421:0.011203:0.011511:0.003421:0.011067:0.005131:0.016044:0.011682:0.003421:0.003421:0.011511:0.010434:0.011682:0.010434:0.011067:0.003421:0.011118:0.006636:0.005131:0.003421:0.010434:0.005131:0.009168:0.010399:0.005679
rope by morphologic subtype: results of the :@0.120589:0.303594:0.479907:0.303594:0.479907:0.289589:0.120589:0.289589:0.005078:0.011203:0.011665:0.011118:0.004023:0.011665:0.009168:0.004037:0.016044:0.011203:0.005148:0.011665:0.010434:0.011203:0.003421:0.011203:0.011511:0.003421:0.011067:0.004014:0.006636:0.010399:0.011665:0.005798:0.009168:0.011665:0.011118:0.004738:0.004028:0.005078:0.011118:0.006636:0.010399:0.003421:0.005798:0.006636:0.004037:0.011203:0.005371:0.004023:0.005798:0.010434:0.011118:0.004738
HAEMACARE  project. :@0.120589:0.317270:0.305084:0.317270:0.305084:0.303265:0.120589:0.303265:0.011682:0.012657:0.009168:0.015719:0.012657:0.013906:0.012657:0.010382:0.009168:0.004738:0.002880:0.011665:0.005080:0.011203:0.003472:0.011118:0.011067:0.005798:0.004738:0.004738
Blood. :@0.307967:0.317270:0.364805:0.317270:0.364805:0.303265:0.307967:0.303265:0.009818:0.003421:0.011203:0.011203:0.011716:0.004738:0.004738
2010;116(19):@0.367696:0.317270:0.470349:0.317270:0.470349:0.303265:0.367696:0.303265:0.009476:0.009476:0.009486:0.009476:0.004738:0.009476:0.009476:0.009476:0.006312:0.009476:0.009476:0.006312
: :@0.470373:0.317270:0.479952:0.317270:0.479952:0.303018:0.470373:0.303018:0.004789:0.004789
3724-3734. e-pub 2010/07/29; Doi: 10.1182/:@0.120589:0.330946:0.475130:0.330946:0.475130:0.316941:0.120589:0.316941:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.009476:0.004738:0.005299:0.011118:0.005679:0.011665:0.010399:0.011665:0.005273:0.009476:0.009476:0.009476:0.009476:0.007475:0.009476:0.009476:0.007475:0.009476:0.009476:0.004738:0.005299:0.012726:0.011203:0.003421:0.004738:0.005272:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.009476:0.007475
blood-2010-05-282632.:@0.120589:0.344622:0.305282:0.344622:0.305282:0.330617:0.120589:0.330617:0.011665:0.003421:0.011203:0.011203:0.011716:0.005679:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.009476:0.009476:0.009476:0.004738
4. :@0.084242:0.358298:0.103194:0.358298:0.103194:0.344293:0.084242:0.344293:0.009476:0.004738:0.004738
 Parkin DM. The evolution of the population-:@0.120589:0.358298:0.475159:0.358298:0.475159:0.344293:0.120589:0.344293:0.000000:0.010126:0.011682:0.005148:0.008586:0.003421:0.010434:0.004362:0.012726:0.015719:0.004738:0.004367:0.007286:0.010434:0.011118:0.004365:0.011118:0.009476:0.011203:0.003421:0.010399:0.005798:0.003421:0.011203:0.010434:0.004362:0.011203:0.005371:0.004363:0.005798:0.010434:0.011118:0.004365:0.011665:0.011203:0.011665:0.010399:0.003421:0.011682:0.005798:0.003421:0.011203:0.010434:0.005679
based cancer  registry. :@0.120589:0.371974:0.321042:0.371974:0.321042:0.357969:0.120589:0.357969:0.011665:0.011682:0.006636:0.011118:0.011716:0.009886:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738:0.005140:0.005078:0.011118:0.011511:0.003421:0.006636:0.005798:0.005148:0.009168:0.004738:0.004738
Nat Rev Cancer. :@0.326190:0.371974:0.479907:0.371974:0.479907:0.357969:0.326190:0.357969:0.012657:0.011682:0.005798:0.009886:0.010382:0.011118:0.009476:0.009886:0.013906:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738:0.004738
2006;6(8) 603-612. Doi: 10.1038/nrc1948.:@0.120589:0.385650:0.446711:0.385650:0.446711:0.371645:0.120589:0.371645:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.006312:0.009476:0.006312:0.004806:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738:0.004738:0.012726:0.011203:0.003421:0.004738:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.009476:0.007475:0.010434:0.005056:0.011067:0.009476:0.009476:0.009476:0.009476:0.004738
::@0.194822:0.385650:0.199611:0.385650:0.199611:0.371398:0.194822:0.371398:0.004789
5. :@0.084242:0.399326:0.103194:0.399326:0.103194:0.385321:0.084242:0.385321:0.009476:0.004738:0.004738
 Parkin DM, Sitas F, Chirenje M, :@0.120589:0.399326:0.376243:0.399326:0.376243:0.385321:0.120589:0.385321:0.000000:0.010126:0.011682:0.005148:0.008586:0.003421:0.010434:0.006380:0.012726:0.015719:0.004738:0.006380:0.008518:0.003421:0.005798:0.011682:0.006636:0.006380:0.006205:0.004738:0.006380:0.013906:0.010434:0.003421:0.005078:0.011118:0.010434:0.003472:0.011118:0.006380:0.015719:0.004738:0.004738
et al:@0.377885:0.399326:0.416284:0.399326:0.416284:0.385321:0.377885:0.385321:0.011118:0.005798:0.006380:0.011682:0.003421
. Part I: :@0.416284:0.399326:0.479878:0.399326:0.479878:0.385321:0.416284:0.385321:0.004738:0.006380:0.010126:0.011682:0.005148:0.005798:0.006380:0.003866:0.004738:0.004738
Cancer  in Indigenous  Africans  --  burden, :@0.120589:0.413002:0.479902:0.413002:0.479902:0.398997:0.120589:0.398997:0.013906:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738:0.004004:0.003421:0.010434:0.008757:0.003866:0.010434:0.011716:0.003421:0.011511:0.011118:0.010434:0.011203:0.010399:0.006636:0.004738:0.004006:0.012657:0.005371:0.005148:0.003421:0.011067:0.011682:0.010434:0.006636:0.004738:0.004008:0.005679:0.005679:0.004738:0.004011:0.011665:0.010399:0.005046:0.011716:0.011118:0.010434:0.004738:0.004738
distribution,  and  trends. :@0.120589:0.426678:0.337322:0.426678:0.337322:0.412673:0.120589:0.412673:0.011716:0.003421:0.006636:0.005798:0.005148:0.003421:0.011665:0.010399:0.005798:0.003421:0.011203:0.010434:0.004738:0.004738:0.009684:0.011682:0.010434:0.011716:0.004738:0.009686:0.005798:0.005075:0.011118:0.010434:0.011716:0.006636:0.004738:0.004738
Lancet  Oncol. :@0.347017:0.426678:0.479904:0.426678:0.479904:0.412673:0.347017:0.412673:0.007902:0.011682:0.010434:0.011067:0.011118:0.005798:0.004738:0.009684:0.014864:0.010434:0.011067:0.011203:0.003421:0.004738:0.004738
2008;9(7) 683-692.  e-pub 2008/07/05; Doi: :@0.120589:0.440354:0.479885:0.440354:0.479885:0.426349:0.120589:0.426349:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.006312:0.009476:0.006312:0.004806:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738:0.004738:0.005318:0.011118:0.005679:0.011665:0.010399:0.011665:0.010040:0.009476:0.009476:0.009476:0.009476:0.007475:0.009476:0.009496:0.007475:0.009476:0.009476:0.004738:0.010040:0.012726:0.011203:0.003421:0.004738:0.004738
::@0.194822:0.440354:0.199611:0.440354:0.199611:0.426102:0.194822:0.426102:0.004789
10.1016/s1470-2045(08)70175-x.:@0.120589:0.454030:0.375359:0.454030:0.375359:0.440025:0.120589:0.440025:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.009476:0.007475:0.006636:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.009476:0.006312:0.009476:0.009476:0.006312:0.009476:0.009476:0.009476:0.009476:0.009476:0.005679:0.008210:0.004738
6. :@0.084242:0.467706:0.103194:0.467706:0.103194:0.453701:0.084242:0.453701:0.009479:0.004734:0.004738
 Patel M, Philip V, Fazel F. Human immuno- :@0.120587:0.467706:0.479883:0.467706:0.479883:0.453701:0.120587:0.453701:0.000000:0.009613:0.011169:0.005285:0.010605:0.002908:0.009219:0.015206:0.004225:0.009219:0.009613:0.009921:0.002908:0.002908:0.002908:0.011152:0.009219:0.009684:0.004225:0.009219:0.007782:0.011169:0.006756:0.010605:0.002908:0.009219:0.006428:0.004225:0.009219:0.011169:0.009886:0.015531:0.011169:0.009921:0.009219:0.002908:0.015531:0.015531:0.009886:0.009921:0.010690:0.005679:0.004738
deficiency  virus  infection  and  Hodgkin’s :@0.120589:0.481382:0.479895:0.481382:0.479895:0.467377:0.120589:0.467377:0.011203:0.010605:0.003908:0.003908:0.010553:0.002908:0.010605:0.009921:0.010553:0.008655:0.004738:0.010812:0.008963:0.002908:0.004635:0.009886:0.006123:0.004738:0.010812:0.002908:0.009921:0.004858:0.010605:0.010553:0.005285:0.002908:0.010690:0.009921:0.004738:0.010813:0.011169:0.009921:0.011203:0.004738:0.010812:0.011169:0.010690:0.011203:0.010998:0.008073:0.002908:0.009921:0.005490:0.006640:0.004738
lymphoma  in  South  Africa:  an  emerging :@0.120589:0.495058:0.479902:0.495058:0.479902:0.481053:0.120589:0.481053:0.002908:0.008655:0.015531:0.011152:0.009921:0.010690:0.015531:0.011169:0.004738:0.008082:0.002908:0.009921:0.004738:0.008082:0.008005:0.010690:0.009886:0.005285:0.009921:0.004738:0.008082:0.012144:0.004858:0.004635:0.002908:0.010553:0.011169:0.004225:0.004738:0.008082:0.011169:0.009921:0.004738:0.008082:0.010605:0.015531:0.010605:0.004649:0.010998:0.002908:0.009921:0.011508:0.004738
problem. :@0.120589:0.508734:0.196155:0.508734:0.196155:0.494729:0.120589:0.494729:0.011152:0.004565:0.010690:0.011152:0.002908:0.010605:0.015531:0.004225:0.004738
Adv Hematol. :@0.205119:0.508734:0.327449:0.508734:0.327449:0.494729:0.205119:0.494729:0.012144:0.011203:0.008963:0.013701:0.011169:0.010605:0.015531:0.011169:0.005285:0.010690:0.002908:0.004225:0.004738
2011;2011 578163. :@0.336412:0.508734:0.479900:0.508734:0.479900:0.494729:0.336412:0.494729:0.008963:0.008963:0.008963:0.008963:0.004225:0.008963:0.008963:0.008963:0.009476:0.003780:0.008963:0.008963:0.008963:0.008963:0.008963:0.008963:0.004755:0.004738
::@0.412338:0.508734:0.417127:0.508734:0.417127:0.494482:0.412338:0.494482:0.004789
e-pub:@0.120606:0.522410:0.168567:0.522410:0.168567:0.508405:0.120606:0.508405:0.010605:0.005166:0.011152:0.009886:0.011152
2011/02/19;:@0.194685:0.522410:0.284534:0.522410:0.284534:0.508405:0.194685:0.508405:0.008963:0.008963:0.008963:0.008963:0.006961:0.008963:0.008963:0.006961:0.008963:0.008963:0.004225
Doi::@0.310653:0.522410:0.340688:0.522410:0.340688:0.508405:0.310653:0.508405:0.012213:0.010690:0.002908:0.004225
10.1155/2011/ :@0.366806:0.522410:0.479900:0.522410:0.479900:0.508405:0.366806:0.508405:0.008963:0.008963:0.004225:0.008963:0.008963:0.008963:0.008963:0.006961:0.008963:0.008963:0.008963:0.008963:0.007543:0.004738
578163.:@0.120606:0.536086:0.179120:0.536086:0.179120:0.522081:0.120606:0.522081:0.008963:0.008963:0.008963:0.008963:0.008963:0.008963:0.004738
7. :@0.084259:0.549762:0.103211:0.549762:0.103211:0.535757:0.084259:0.535757:0.009476:0.004738:0.004738
 Wiggill  TM, Mantina H, Willem  P, :@0.120606:0.549762:0.419000:0.549762:0.419000:0.535757:0.120606:0.535757:0.000000:0.016519:0.003421:0.011511:0.011511:0.003421:0.003421:0.003421:0.004738:0.007348:0.007286:0.015719:0.004738:0.012076:0.015719:0.011682:0.010434:0.005798:0.003421:0.010434:0.011682:0.012076:0.011682:0.004738:0.012076:0.016519:0.003421:0.003421:0.003421:0.011118:0.016044:0.004738:0.007348:0.008017:0.004738:0.004738
et al.:@0.426338:0.549762:0.475171:0.549762:0.475171:0.535757:0.426338:0.535757:0.011118:0.005798:0.012076:0.011682:0.003421:0.004738
 :@0.475171:0.549762:0.479909:0.549762:0.479909:0.535757:0.475171:0.535757:0.004738
Changing pattern of lymphoma subgroups :@0.120606:0.563438:0.479904:0.563438:0.479904:0.549433:0.120606:0.549433:0.013906:0.010434:0.011682:0.010434:0.011511:0.003421:0.010434:0.011511:0.004445:0.011665:0.011682:0.005798:0.005798:0.011118:0.005502:0.010434:0.004451:0.011203:0.005371:0.004449:0.003421:0.009168:0.016044:0.011665:0.010434:0.011203:0.016044:0.011682:0.004456:0.006636:0.010399:0.011665:0.011511:0.005077:0.011203:0.010399:0.011665:0.006636:0.004738
at a tertiary academic complex in a high-:@0.120606:0.577549:0.475180:0.577549:0.475180:0.563544:0.120606:0.563544:0.011682:0.005798:0.005798:0.011682:0.005798:0.005798:0.011118:0.005148:0.005798:0.003421:0.011682:0.005148:0.009168:0.005798:0.011682:0.011067:0.011682:0.011716:0.011118:0.016044:0.003421:0.011067:0.005798:0.011067:0.011203:0.016044:0.011665:0.003421:0.011118:0.008210:0.005798:0.003421:0.010434:0.005798:0.011682:0.005798:0.010434:0.003421:0.011511:0.010434:0.005679
prevalence  HIV setting:  a South  African :@0.120606:0.591660:0.479924:0.591660:0.479924:0.577655:0.120606:0.577655:0.011665:0.005080:0.011118:0.009476:0.011682:0.003421:0.011118:0.010434:0.011067:0.011118:0.004738:0.005978:0.011682:0.003866:0.012007:0.010724:0.006636:0.011118:0.005798:0.005798:0.003421:0.010434:0.011511:0.004738:0.004738:0.005969:0.011682:0.010724:0.008518:0.011203:0.010399:0.005798:0.010423:0.004738:0.005978:0.012657:0.005371:0.005148:0.003421:0.011067:0.011682:0.010434:0.004738
perspective. :@0.120606:0.605772:0.228312:0.605772:0.228312:0.591766:0.120606:0.591766:0.011665:0.011118:0.005148:0.006636:0.011665:0.011118:0.011067:0.005798:0.003421:0.009476:0.011118:0.004738:0.004738
J Acquir Immune Defic Syndr. :@0.229202:0.605772:0.479914:0.605772:0.479914:0.591766:0.229202:0.591766:0.008244:0.005627:0.012657:0.011067:0.011665:0.010399:0.003421:0.005148:0.005629:0.003866:0.016044:0.016044:0.010399:0.010434:0.011118:0.005624:0.012726:0.011118:0.004165:0.004165:0.011067:0.005626:0.008518:0.009168:0.010434:0.011716:0.005148:0.004738:0.004738
2011;56(5) 460-466. e-pub 2011/01/18; Doi: :@0.120606:0.619883:0.479914:0.619883:0.479914:0.605877:0.120606:0.605877:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.006312:0.009476:0.006312:0.004823:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738:0.006896:0.011118:0.005679:0.011665:0.010399:0.011665:0.006876:0.009476:0.009476:0.009476:0.009476:0.007475:0.009476:0.009476:0.007475:0.009476:0.009476:0.004738:0.006903:0.012726:0.011203:0.003421:0.004738:0.004738
::@0.204332:0.619883:0.209121:0.619883:0.209121:0.605630:0.204332:0.605630:0.004789
10.1097/QAI.0b013e31820bb06a.:@0.120606:0.633994:0.392600:0.633994:0.392600:0.619989:0.120606:0.619989:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.009476:0.007475:0.014898:0.012657:0.003866:0.004738:0.009476:0.011665:0.009476:0.009476:0.009476:0.011118:0.009476:0.009476:0.009476:0.009476:0.009476:0.011665:0.011665:0.009476:0.009476:0.011682:0.004738
8. :@0.084259:0.648105:0.103211:0.648105:0.103211:0.634100:0.084259:0.634100:0.009476:0.004738:0.004738
 WHO report 2011. :@0.120606:0.648105:0.270157:0.648105:0.270157:0.634100:0.120606:0.634100:0.000000:0.016420:0.011682:0.014864:0.004601:0.005078:0.011118:0.011665:0.011203:0.005148:0.005798:0.004593:0.009476:0.009476:0.009476:0.009476:0.004738:0.004738
Global Tuberculosis Con-:@0.270030:0.648105:0.475163:0.648105:0.475163:0.634100:0.270030:0.634100:0.014915:0.003421:0.011203:0.011665:0.011682:0.003421:0.004601:0.007286:0.010399:0.011665:0.011118:0.005148:0.011067:0.010399:0.003421:0.011203:0.006636:0.003421:0.006636:0.004601:0.013906:0.011203:0.010434:0.005679
trol:@0.120606:0.662216:0.146177:0.662216:0.146177:0.648211:0.120606:0.648211:0.005798:0.005148:0.011203:0.003421
.  Geneva:  World  Health  Organization :@0.146177:0.662216:0.479923:0.662216:0.479923:0.648211:0.146177:0.648211:0.004738:0.004738:0.005923:0.014915:0.011118:0.010434:0.011118:0.009476:0.011682:0.004738:0.004738:0.005925:0.015635:0.011203:0.005148:0.003421:0.011716:0.004738:0.005922:0.011682:0.011118:0.011682:0.003421:0.005798:0.010434:0.004738:0.005925:0.014864:0.005164:0.011511:0.011682:0.010434:0.003421:0.007269:0.011682:0.005798:0.003421:0.011203:0.010434:0.004738
2011.:@0.120606:0.676327:0.163247:0.676327:0.163247:0.662322:0.120606:0.662322:0.009476:0.009476:0.009476:0.009476:0.004738
9. :@0.084259:0.690438:0.103211:0.690438:0.103211:0.676433:0.084259:0.676433:0.009476:0.004738:0.004738
 Coutinho  R, Pria AD, Gandhi S, :@0.120606:0.690438:0.392348:0.690438:0.392348:0.676433:0.120606:0.676433:0.000000:0.013906:0.011203:0.010399:0.005798:0.003421:0.010434:0.010434:0.011203:0.004738:0.002998:0.010382:0.004738:0.007748:0.010126:0.005148:0.003421:0.011682:0.007748:0.012657:0.012726:0.004738:0.007748:0.014915:0.011682:0.010434:0.011716:0.010434:0.003421:0.007748:0.008518:0.004738:0.004738
et al.:@0.395359:0.690438:0.439864:0.690438:0.439864:0.676433:0.395359:0.676433:0.011118:0.005798:0.007748:0.011682:0.003421:0.004738
 HIV :@0.439864:0.690438:0.479906:0.690438:0.479906:0.676433:0.439864:0.676433:0.007748:0.011682:0.003866:0.012007:0.004738
status does not impair the outcome of pa-:@0.120606:0.704549:0.475166:0.704549:0.475166:0.690544:0.120606:0.690544:0.006636:0.005798:0.011682:0.005798:0.010399:0.006636:0.005482:0.011716:0.011203:0.011118:0.006636:0.005479:0.010434:0.011203:0.005798:0.005470:0.003421:0.016044:0.011665:0.011682:0.003421:0.005148:0.005490:0.005798:0.010434:0.011118:0.005473:0.011203:0.010399:0.005798:0.011067:0.011203:0.016032:0.011118:0.005477:0.011203:0.005371:0.005475:0.011665:0.011682:0.005679
tients diagnosed with diffuse large B-cell :@0.120606:0.718660:0.479887:0.718660:0.479887:0.704655:0.120606:0.704655:0.005798:0.003421:0.011118:0.010434:0.005798:0.006636:0.009305:0.011716:0.003421:0.011682:0.011511:0.010434:0.011203:0.006636:0.011118:0.011716:0.009305:0.014214:0.003421:0.005798:0.010434:0.009305:0.011716:0.003421:0.005424:0.005371:0.010399:0.006636:0.011118:0.009305:0.003421:0.011682:0.005167:0.011511:0.011118:0.009305:0.009818:0.005679:0.011067:0.011118:0.003421:0.003421:0.004738
lymphoma treated with R-CHOP in the :@0.560000:0.094867:0.919306:0.094867:0.919306:0.080862:0.560000:0.080862:0.003421:0.009168:0.016044:0.011665:0.010434:0.011203:0.016044:0.011682:0.012178:0.005798:0.005075:0.011118:0.011682:0.005798:0.011118:0.011716:0.012178:0.014214:0.003421:0.005798:0.010434:0.012178:0.010382:0.005679:0.013906:0.011682:0.014864:0.010126:0.012178:0.003421:0.010434:0.012178:0.005798:0.010434:0.011118:0.004738
cART era. :@0.560000:0.109378:0.646933:0.109378:0.646933:0.095373:0.560000:0.095373:0.011067:0.012657:0.010476:0.007286:0.008022:0.011118:0.005148:0.011682:0.004738:0.004738
AIDS. :@0.650217:0.109378:0.697459:0.109378:0.697459:0.095373:0.650217:0.095373:0.012657:0.003866:0.012726:0.008518:0.004738:0.004738
2014  Mar 13;28(5):689-97. :@0.700735:0.109378:0.919274:0.109378:0.919274:0.095373:0.700735:0.095373:0.009476:0.009476:0.009476:0.009476:0.004738:0.003301:0.015719:0.011682:0.005148:0.008022:0.009476:0.009476:0.004738:0.009476:0.009476:0.006325:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.004738:0.004738
Doi: 10.1097/QAD.0000000000000133.:@0.560000:0.123889:0.867263:0.123889:0.867263:0.109884:0.560000:0.109884:0.012726:0.011203:0.003421:0.004738:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.009476:0.007475:0.014898:0.012657:0.012726:0.004738:0.009476:0.009476:0.009476:0.009476:0.009476:0.009476:0.009476:0.009476:0.009476:0.009476:0.009476:0.009476:0.009476:0.009476:0.009476:0.009476:0.004738
10.   Swerdlow SH, Campo E, Pileri SA, :@0.523653:0.138400:0.861839:0.138400:0.861839:0.124395:0.523653:0.124395:0.009476:0.009476:0.004738:0.004738:0.007919:0.000000:0.008518:0.014214:0.011118:0.005044:0.011716:0.003421:0.011203:0.014214:0.010348:0.008518:0.011682:0.004738:0.010348:0.013906:0.011682:0.016044:0.011665:0.011203:0.010348:0.009168:0.004738:0.010348:0.010126:0.003421:0.003421:0.011118:0.005148:0.003421:0.010348:0.008518:0.012657:0.004738:0.004738
et al.:@0.867449:0.138400:0.914555:0.138400:0.914555:0.124395:0.867449:0.124395:0.011118:0.005798:0.010348:0.011682:0.003421:0.004738
 :@0.914555:0.138400:0.919293:0.138400:0.919293:0.124395:0.914555:0.124395:0.004738
The 2016  revision of the World Health Or-:@0.560000:0.152911:0.914572:0.152911:0.914572:0.138906:0.560000:0.138906:0.007286:0.010434:0.011118:0.008022:0.009476:0.009476:0.009476:0.009476:0.004738:0.003299:0.005078:0.011118:0.009476:0.003421:0.006636:0.003421:0.011203:0.010434:0.008022:0.011203:0.005371:0.008022:0.005798:0.010434:0.011118:0.008022:0.015635:0.011203:0.005148:0.003421:0.011716:0.008022:0.011682:0.011118:0.011682:0.003421:0.005798:0.010434:0.008022:0.014864:0.005148:0.005679
ganization  classification  of  lymphoid  neo- :@0.560000:0.167422:0.919301:0.167422:0.919301:0.153416:0.560000:0.153416:0.011511:0.011682:0.010434:0.003421:0.007269:0.011682:0.005798:0.003421:0.011203:0.010434:0.004738:0.002964:0.011067:0.003421:0.011682:0.006636:0.006636:0.003435:0.004165:0.004165:0.011067:0.011682:0.005798:0.003421:0.011203:0.010434:0.004738:0.002964:0.011203:0.005371:0.004738:0.002966:0.003421:0.009168:0.016044:0.011665:0.010434:0.011203:0.003421:0.011716:0.004738:0.002969:0.010434:0.011118:0.011203:0.005679:0.004738
plasms. :@0.560000:0.181933:0.627111:0.181933:0.627111:0.167927:0.560000:0.167927:0.011665:0.003421:0.011682:0.006636:0.016567:0.007153:0.005248:0.004738
Blood. :@0.638629:0.181933:0.698545:0.181933:0.698545:0.167927:0.638629:0.167927:0.010331:0.003934:0.011716:0.011716:0.012230:0.005251:0.004738
2016;127(20) 2375-2390.  :@0.710074:0.181933:0.919294:0.181933:0.919294:0.167927:0.710074:0.167927:0.009989:0.009989:0.009989:0.009989:0.005251:0.009989:0.009989:0.009989:0.006825:0.009989:0.009989:0.006312:0.005850:0.009989:0.009989:0.009989:0.009989:0.006192:0.009989:0.009989:0.009989:0.009479:0.004736:0.000000:0.004738
::@0.818875:0.181933:0.823664:0.181933:0.823664:0.167680:0.818875:0.167680:0.004789
e-pub 2016/03/17; Doi: 10.1182/blood-2016- :@0.560000:0.196444:0.919294:0.196444:0.919294:0.182438:0.560000:0.182438:0.011118:0.005679:0.011665:0.010399:0.011665:0.002959:0.009476:0.009476:0.009476:0.009476:0.007475:0.009476:0.009476:0.007475:0.009476:0.009476:0.004738:0.002978:0.012726:0.011203:0.003421:0.004738:0.002959:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.009476:0.007475:0.011665:0.003421:0.011222:0.011203:0.011716:0.005679:0.009476:0.009476:0.009476:0.009476:0.005675:0.004738
01-643569.:@0.560000:0.210954:0.646223:0.210954:0.646223:0.196949:0.560000:0.196949:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.009476:0.009476:0.009476:0.004738
11.   Howell DA, Smith AG, Jack A, :@0.523653:0.225465:0.803258:0.225465:0.803258:0.211460:0.523653:0.211460:0.009479:0.009479:0.004731:0.004738:0.007916:0.000000:0.011340:0.010861:0.013872:0.010776:0.003079:0.003079:0.005542:0.012384:0.012315:0.004396:0.005542:0.008176:0.015702:0.003079:0.005456:0.010092:0.005542:0.012315:0.014573:0.004396:0.005542:0.007902:0.011340:0.010724:0.008244:0.005542:0.012315:0.004396:0.004738
et al.:@0.804062:0.225465:0.844993:0.225465:0.844993:0.211460:0.804062:0.211460:0.010776:0.005456:0.005542:0.011340:0.003079:0.004738
 Time-to-:@0.844651:0.225465:0.914550:0.225465:0.914550:0.211460:0.844651:0.211460:0.005542:0.007468:0.003079:0.015702:0.010776:0.005337:0.005456:0.010861:0.005679
diagnosis  and  symptoms  of  myeloma,  lym-:@0.560000:0.239976:0.914548:0.239976:0.914548:0.225971:0.560000:0.225971:0.011374:0.003079:0.011340:0.011169:0.010092:0.010861:0.006294:0.003079:0.006294:0.004738:0.002831:0.011340:0.010092:0.011374:0.004738:0.002831:0.006294:0.008826:0.015702:0.011323:0.005456:0.010861:0.015702:0.006294:0.004738:0.002831:0.010861:0.005029:0.004738:0.002831:0.015702:0.008826:0.010776:0.003079:0.010861:0.015702:0.011340:0.004396:0.004738:0.002831:0.003079:0.008826:0.015702:0.005679
phomas and leukaemias: a report from the :@0.560000:0.254487:0.919323:0.254487:0.919323:0.240482:0.560000:0.240482:0.011323:0.010092:0.010861:0.015702:0.011340:0.006294:0.006465:0.011340:0.010092:0.011374:0.006465:0.003079:0.010776:0.010057:0.008244:0.011340:0.010776:0.015702:0.003079:0.011340:0.006294:0.004396:0.006465:0.011340:0.006465:0.004736:0.010776:0.011323:0.010861:0.004806:0.005456:0.006465:0.005029:0.004736:0.010861:0.015702:0.006465:0.005456:0.010092:0.011116:0.004738
Haematological Malignancy Research Net-:@0.560000:0.268998:0.914574:0.268998:0.914574:0.254993:0.560000:0.254993:0.011340:0.011340:0.010776:0.015702:0.011340:0.005456:0.010861:0.003079:0.010861:0.011169:0.003079:0.010724:0.011340:0.003079:0.006782:0.015377:0.011340:0.003079:0.003079:0.011169:0.010092:0.011340:0.010092:0.010724:0.008826:0.006790:0.010040:0.010776:0.006294:0.010776:0.011340:0.004687:0.010724:0.010092:0.006782:0.012315:0.010776:0.005456:0.005679
work. :@0.560000:0.283509:0.606917:0.283509:0.606917:0.269504:0.560000:0.269504:0.013872:0.010861:0.004806:0.008244:0.004396:0.004738
BMC Hematology. :@0.607858:0.283509:0.760504:0.283509:0.760504:0.269504:0.607858:0.269504:0.009476:0.015377:0.013564:0.005685:0.011340:0.010776:0.015702:0.011340:0.005456:0.010861:0.003079:0.010861:0.011169:0.008826:0.004396:0.004738
2013;13(1) 9. e-pub :@0.761455:0.283509:0.919303:0.283509:0.919303:0.269504:0.761455:0.269504:0.009134:0.009134:0.009134:0.009134:0.004396:0.009134:0.009134:0.005969:0.009134:0.006312:0.004122:0.009134:0.004396:0.005685:0.010776:0.005337:0.011323:0.010057:0.011667:0.004738
::@0.841726:0.283509:0.846515:0.283509:0.846515:0.269257:0.841726:0.269257:0.004789
2013/11/19; Doi: 10.1186/2052-1839-13-9.:@0.560000:0.298020:0.878791:0.298020:0.878791:0.284015:0.560000:0.284015:0.009134:0.009134:0.009134:0.009134:0.007133:0.009134:0.009134:0.007133:0.009134:0.009134:0.004396:0.004396:0.012384:0.010861:0.003079:0.004396:0.004396:0.009134:0.009134:0.004396:0.009134:0.009134:0.009134:0.009134:0.007133:0.009134:0.009134:0.009134:0.009134:0.005337:0.009134:0.009134:0.009134:0.009134:0.005337:0.009134:0.009134:0.005337:0.009134:0.004738
12.   Wilson D, Nachega J, Morroni C, :@0.523653:0.312531:0.826370:0.312531:0.826370:0.298526:0.523653:0.298526:0.009476:0.009476:0.004738:0.004738:0.007919:0.000000:0.016519:0.003421:0.003421:0.006636:0.011203:0.010434:0.003712:0.012726:0.004738:0.003712:0.012657:0.011682:0.011067:0.010434:0.011118:0.011511:0.011682:0.003712:0.008244:0.004738:0.003712:0.015719:0.011203:0.005148:0.005070:0.011203:0.010434:0.003421:0.003712:0.013906:0.004738:0.004738
et al.:@0.825344:0.312531:0.865812:0.312531:0.865812:0.298526:0.825344:0.298526:0.011118:0.005798:0.003712:0.011682:0.003421:0.004738
 Diag-:@0.865812:0.312531:0.914543:0.312531:0.914543:0.298526:0.865812:0.298526:0.003712:0.012726:0.003421:0.011682:0.011511:0.005679
nosing  smear-negative tuberculosis using :@0.560000:0.327042:0.919311:0.327042:0.919311:0.313037:0.560000:0.313037:0.010434:0.011203:0.006636:0.003421:0.010434:0.011511:0.004738:0.005545:0.006636:0.016044:0.011118:0.011682:0.005148:0.005679:0.010434:0.011118:0.011511:0.011682:0.005798:0.003421:0.009476:0.011118:0.010297:0.005798:0.010399:0.011665:0.011118:0.005025:0.011067:0.010399:0.003421:0.011203:0.006636:0.003421:0.006636:0.010297:0.010399:0.006636:0.003421:0.010434:0.011511:0.004738
case definitions and treatment response in :@0.560000:0.341553:0.919299:0.341553:0.919299:0.327548:0.560000:0.327548:0.011067:0.011682:0.006636:0.011118:0.005426:0.011716:0.011118:0.004165:0.004165:0.010434:0.003421:0.005798:0.003421:0.011203:0.010434:0.006636:0.005419:0.011682:0.010434:0.011716:0.005424:0.005798:0.005075:0.011118:0.011682:0.005798:0.016044:0.011118:0.010434:0.005798:0.005415:0.005078:0.011118:0.006636:0.011665:0.011203:0.010434:0.006636:0.011118:0.005422:0.003421:0.010434:0.004738
HIV-infected adults. :@0.560000:0.356064:0.729761:0.356064:0.729761:0.342058:0.560000:0.342058:0.011682:0.003866:0.012007:0.005679:0.003421:0.010434:0.005371:0.011118:0.011067:0.005798:0.011118:0.011716:0.007355:0.011682:0.011716:0.010399:0.003421:0.005798:0.006636:0.004738:0.004738
Int J Tuberc  Lung  Dis. :@0.732378:0.356064:0.919305:0.356064:0.919305:0.342058:0.732378:0.342058:0.003866:0.010434:0.005798:0.007355:0.008244:0.007355:0.007286:0.010399:0.011665:0.011118:0.005148:0.011067:0.004738:0.002605:0.007902:0.010399:0.010434:0.011511:0.004738:0.002605:0.012726:0.003421:0.006636:0.004738:0.004738
2006;10(1) 31-38. e-Pub 2006/02/10.:@0.560000:0.370575:0.850791:0.370575:0.850791:0.356569:0.560000:0.356569:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.006312:0.009476:0.006312:0.004823:0.009476:0.009476:0.005679:0.009476:0.009476:0.004738:0.004738:0.011118:0.005679:0.010126:0.010399:0.011665:0.004738:0.009476:0.009476:0.009476:0.009476:0.007475:0.009476:0.009476:0.007475:0.009476:0.009476:0.004738
::@0.643726:0.370575:0.648515:0.370575:0.648515:0.356322:0.643726:0.356322:0.004789
13.   Kostakoglu L, Cheson BD. Current role of :@0.523653:0.385086:0.919318:0.385086:0.919318:0.371080:0.523653:0.371080:0.009476:0.009476:0.004738:0.004738:0.007919:0.000000:0.010109:0.011203:0.006636:0.005798:0.011682:0.008586:0.011203:0.011511:0.003421:0.010399:0.008518:0.007902:0.004738:0.008518:0.013906:0.010434:0.011118:0.006636:0.011203:0.010434:0.008518:0.009818:0.012726:0.004738:0.008518:0.013906:0.010399:0.005148:0.005071:0.011118:0.010434:0.005798:0.008518:0.005078:0.011203:0.003421:0.011118:0.008518:0.011203:0.005371:0.004738
FDG PET/CT in lymphoma. :@0.560000:0.399597:0.783920:0.399597:0.783920:0.385591:0.560000:0.385591:0.008296:0.012726:0.014915:0.006585:0.010126:0.009168:0.007286:0.007475:0.013906:0.007286:0.006575:0.003421:0.010434:0.006585:0.003421:0.009168:0.016044:0.011665:0.010434:0.011203:0.016044:0.011682:0.004738:0.004738
Eur J Nucl Med :@0.785767:0.399597:0.919318:0.399597:0.919318:0.385591:0.785767:0.385591:0.009168:0.010399:0.005148:0.006585:0.008244:0.006585:0.012657:0.010399:0.011067:0.003421:0.006585:0.015719:0.011118:0.011716:0.004738
Mol Imaging. :@0.560000:0.414107:0.673407:0.414107:0.673407:0.400102:0.560000:0.400102:0.015719:0.011203:0.003421:0.005119:0.003866:0.016044:0.011682:0.011511:0.003421:0.010434:0.011511:0.004738:0.004738
2014;41(5) 1004-1027. Doi: 10. :@0.673778:0.414107:0.919298:0.414107:0.919298:0.400102:0.673778:0.400102:0.009476:0.009476:0.009486:0.009476:0.004738:0.009476:0.009476:0.006312:0.009476:0.006312:0.004813:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009500:0.009476:0.004738:0.005123:0.012726:0.011203:0.003421:0.004738:0.005119:0.009476:0.009476:0.004738:0.004738
::@0.757504:0.414107:0.762293:0.414107:0.762293:0.399855:0.757504:0.399855:0.004789
1007/s00259-013-2686-2.:@0.560000:0.428618:0.756974:0.428618:0.756974:0.414613:0.560000:0.414613:0.009476:0.009476:0.009476:0.009476:0.007475:0.006636:0.009476:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.004738
14.   Borchmann P, Haverkamp H, Diehl V, :@0.523653:0.443129:0.871311:0.443129:0.871311:0.429124:0.523653:0.429124:0.009476:0.009476:0.004738:0.004738:0.007919:0.000000:0.009818:0.011203:0.005029:0.011067:0.010434:0.016044:0.011682:0.010434:0.010434:0.005615:0.008017:0.004738:0.005619:0.011682:0.011682:0.009476:0.011118:0.005148:0.008586:0.011682:0.016044:0.011665:0.005627:0.011682:0.004738:0.005627:0.012726:0.003421:0.011118:0.010434:0.003421:0.005627:0.010198:0.004738:0.004738
et al.:@0.872189:0.443129:0.914563:0.443129:0.914563:0.429124:0.872189:0.429124:0.011118:0.005798:0.005617:0.011682:0.003421:0.004738
 :@0.914563:0.443129:0.919301:0.443129:0.919301:0.429124:0.914563:0.429124:0.004738
Eight cycles of escalated-dose BEACOPP :@0.560000:0.457640:0.919311:0.457640:0.919311:0.443635:0.560000:0.443635:0.009168:0.003421:0.011511:0.010434:0.005798:0.008484:0.011067:0.009168:0.011067:0.003421:0.011118:0.006636:0.008484:0.011203:0.005371:0.008484:0.011118:0.006636:0.011067:0.011682:0.003421:0.011682:0.005798:0.011118:0.011716:0.005679:0.011716:0.011203:0.006636:0.011118:0.008484:0.009818:0.009168:0.012657:0.013906:0.014864:0.010126:0.010126:0.004738
compared with four cycles of escalated-:@0.560000:0.472151:0.914555:0.472151:0.914555:0.458146:0.560000:0.458146:0.011067:0.011203:0.016044:0.011665:0.011682:0.005078:0.011118:0.011716:0.008005:0.014214:0.003421:0.005798:0.010434:0.008005:0.005371:0.011203:0.010399:0.005148:0.008005:0.011067:0.009168:0.011067:0.003421:0.011118:0.006636:0.008005:0.011203:0.005371:0.008005:0.011118:0.006636:0.011067:0.011682:0.003421:0.011682:0.005798:0.011118:0.011716:0.005679
dose BEACOPP followed by four cycles of :@0.560000:0.486662:0.919310:0.486662:0.919310:0.472657:0.560000:0.472657:0.011716:0.011203:0.006636:0.011118:0.006592:0.009818:0.009168:0.012657:0.013906:0.014864:0.010126:0.010126:0.006589:0.005371:0.011203:0.003421:0.003421:0.011203:0.014214:0.011118:0.011716:0.006592:0.011665:0.009168:0.006602:0.005371:0.011203:0.010399:0.005148:0.006583:0.011067:0.009168:0.011067:0.003421:0.011118:0.006636:0.006602:0.011203:0.005371:0.004738
baseline-dose BEACOPP  with or without :@0.560000:0.501173:0.919317:0.501173:0.919317:0.487168:0.560000:0.487168:0.011665:0.011682:0.006636:0.011118:0.003421:0.003421:0.010434:0.011118:0.005679:0.011716:0.011203:0.006636:0.011118:0.011648:0.009818:0.009168:0.012657:0.013906:0.014864:0.010126:0.010126:0.004738:0.006898:0.014214:0.003421:0.005798:0.010434:0.011648:0.011203:0.005148:0.011648:0.014214:0.003421:0.005798:0.010434:0.011203:0.010399:0.005798:0.004738
radiotherapy  in patients with  advanced-:@0.560000:0.515684:0.914568:0.515684:0.914568:0.501679:0.560000:0.501679:0.005148:0.011682:0.011716:0.003421:0.011203:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.004738:0.004639:0.003421:0.010434:0.009390:0.011665:0.011682:0.005798:0.003421:0.011118:0.010434:0.005798:0.006636:0.009390:0.014214:0.003421:0.005798:0.010434:0.004738:0.004644:0.011682:0.011716:0.009476:0.011682:0.010434:0.011067:0.011118:0.011716:0.005679
stage  Hodgkin’s  lymphoma:  final  analysis :@0.560000:0.530195:0.919293:0.530195:0.919293:0.516190:0.560000:0.516190:0.006636:0.005798:0.011682:0.011511:0.011118:0.004738:0.004076:0.011682:0.011203:0.011716:0.011511:0.008586:0.003421:0.010434:0.006004:0.006636:0.004738:0.004081:0.003421:0.009168:0.016044:0.011665:0.010434:0.011203:0.016044:0.011682:0.004738:0.004738:0.004078:0.004165:0.004165:0.010434:0.011682:0.003421:0.004738:0.004081:0.011682:0.010434:0.011682:0.003421:0.009168:0.006636:0.003421:0.006636:0.004738
of the HD12 trial of the German Hodgkin’s :@0.560000:0.544706:0.919288:0.544706:0.919288:0.530700:0.560000:0.530700:0.011203:0.005371:0.006123:0.005798:0.010434:0.011118:0.006123:0.011682:0.012726:0.009476:0.009476:0.006123:0.005798:0.005148:0.003421:0.011682:0.003421:0.006123:0.011203:0.005371:0.006123:0.005798:0.010434:0.011118:0.006123:0.014915:0.011118:0.005620:0.016044:0.011682:0.010434:0.006123:0.011682:0.011203:0.011716:0.011511:0.008586:0.003421:0.010434:0.006004:0.006636:0.004738
Study Group. :@0.560000:0.559217:0.671185:0.559217:0.671185:0.545211:0.560000:0.545211:0.008518:0.005798:0.010399:0.011716:0.009168:0.002848:0.014915:0.005078:0.011203:0.010399:0.011665:0.004738:0.004738
J Clin Oncol. :@0.669297:0.559217:0.774881:0.559217:0.774881:0.545211:0.669297:0.545211:0.008244:0.002846:0.013906:0.003421:0.003421:0.010434:0.002848:0.014864:0.010434:0.011067:0.011203:0.003421:0.004738:0.004738
2011;29(32) 4234-:@0.772984:0.559217:0.914556:0.559217:0.914556:0.545211:0.772984:0.545211:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009495:0.006312:0.009476:0.009476:0.006312:0.004805:0.009476:0.009476:0.009476:0.009476:0.005679
::@0.866185:0.559217:0.870975:0.559217:0.870975:0.544964:0.866185:0.544964:0.004789
4242. Doi: 10.1200/JCO.2010.33.9549.:@0.560000:0.573728:0.863996:0.573728:0.863996:0.559722:0.560000:0.559722:0.009476:0.009476:0.009476:0.009476:0.004738:0.004738:0.012726:0.011203:0.003421:0.004738:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.009476:0.007475:0.008244:0.013906:0.014864:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738
15.   Connors  JM. Non-Hodgkin’s  lymphoma: :@0.523653:0.588239:0.919306:0.588239:0.919306:0.574233:0.523653:0.574233:0.009476:0.009476:0.004738:0.004738:0.007919:0.000000:0.013906:0.011203:0.010434:0.010434:0.011203:0.005148:0.006636:0.004738:0.009035:0.008244:0.015719:0.004738:0.013786:0.012657:0.011203:0.010434:0.005679:0.011682:0.011203:0.011716:0.011511:0.008586:0.003421:0.010434:0.006004:0.006636:0.004738:0.009040:0.003421:0.009168:0.016044:0.011665:0.010434:0.011203:0.016044:0.011682:0.004738:0.004738
the  clinician’s  perspective – a view from :@0.560000:0.602749:0.919310:0.602749:0.919310:0.588744:0.560000:0.588744:0.005798:0.010434:0.011118:0.004738:0.003890:0.011067:0.003421:0.003421:0.010434:0.003421:0.011067:0.003421:0.011682:0.010434:0.006004:0.006636:0.004738:0.003910:0.011665:0.011118:0.005148:0.006636:0.011665:0.011118:0.011067:0.005798:0.003421:0.009476:0.011118:0.008638:0.008552:0.008638:0.011682:0.008638:0.009476:0.003421:0.011118:0.014214:0.008638:0.005371:0.005078:0.011203:0.016044:0.004738
the  receiving end. :@0.560000:0.617260:0.728716:0.617260:0.728716:0.603255:0.560000:0.603255:0.005798:0.010434:0.011118:0.004738:0.006243:0.005078:0.011118:0.011067:0.011118:0.003421:0.009476:0.003421:0.010434:0.011511:0.010998:0.011118:0.010434:0.011716:0.004738:0.004738
Mod  Pathol. :@0.734944:0.617260:0.846697:0.617260:0.846697:0.603255:0.734944:0.603255:0.015719:0.011203:0.011716:0.004738:0.006245:0.010126:0.011682:0.005798:0.010434:0.011195:0.003421:0.004738:0.004738
2013;26 :@0.852947:0.617260:0.919277:0.617260:0.919277:0.603255:0.852947:0.603255:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.004738
(Suppl1):S111-118. Doi: 10.1038/modpathol. :@0.560000:0.631771:0.919303:0.631771:0.919303:0.617766:0.560000:0.617766:0.006312:0.008518:0.010399:0.011665:0.011665:0.003421:0.009476:0.006312:0.004738:0.008518:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738:0.003614:0.012726:0.011203:0.003421:0.004738:0.003580:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.009476:0.007475:0.016044:0.011219:0.011716:0.011665:0.011682:0.005798:0.010434:0.011203:0.003421:0.004738:0.004738
2012.184.:@0.560000:0.646282:0.635807:0.646282:0.635807:0.632277:0.560000:0.632277:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.004738
16.   Vogt SLP, Omar, T, Pather S, :@0.523653:0.660793:0.785064:0.660793:0.785064:0.646788:0.523653:0.646788:0.009476:0.009476:0.004738:0.004738:0.007919:0.000000:0.010281:0.011203:0.011511:0.005798:0.004762:0.008518:0.007902:0.008019:0.004738:0.004772:0.014864:0.016044:0.011682:0.003351:0.004738:0.004772:0.005538:0.004738:0.004772:0.010126:0.011682:0.005798:0.010434:0.011118:0.005148:0.004760:0.008518:0.004738:0.004738
et al.:@0.785099:0.660793:0.826628:0.660793:0.826628:0.646788:0.785099:0.646788:0.011118:0.005798:0.004772:0.011682:0.003421:0.004738
 Molecular :@0.826628:0.660793:0.919317:0.660793:0.919317:0.646788:0.826628:0.646788:0.004772:0.015719:0.011203:0.003421:0.011118:0.011067:0.010399:0.003421:0.011682:0.005148:0.004738
diagnostics for  AIDS lymphoma diagnosis :@0.560000:0.675304:0.919298:0.675304:0.919298:0.661299:0.560000:0.661299:0.011716:0.003421:0.011682:0.011511:0.010434:0.011203:0.006636:0.005798:0.003421:0.011067:0.006636:0.008809:0.005371:0.011203:0.005148:0.004738:0.004057:0.012657:0.003866:0.012726:0.008518:0.008809:0.003421:0.009168:0.016044:0.011665:0.010434:0.011203:0.016044:0.011682:0.008809:0.011716:0.003421:0.011682:0.011511:0.010434:0.011203:0.006636:0.003421:0.006636:0.004738
in South Africa and the potential for other :@0.560000:0.689815:0.919334:0.689815:0.919334:0.675810:0.560000:0.675810:0.003421:0.010434:0.006277:0.008518:0.011203:0.010399:0.005798:0.010434:0.006264:0.012657:0.005371:0.005148:0.003421:0.011067:0.011682:0.006267:0.011682:0.010434:0.011716:0.006277:0.005798:0.010434:0.011118:0.006267:0.011665:0.011203:0.005798:0.011118:0.010434:0.005798:0.003421:0.011682:0.003421:0.006277:0.005371:0.011203:0.005148:0.006265:0.011203:0.005798:0.010434:0.011118:0.005148:0.004738
low- and middle-income countries. :@0.560000:0.704326:0.853949:0.704326:0.853949:0.690321:0.560000:0.690321:0.003421:0.011203:0.014214:0.005679:0.004841:0.011682:0.010434:0.011716:0.004841:0.016044:0.003421:0.011716:0.011716:0.003421:0.011118:0.005679:0.003421:0.010434:0.011067:0.011203:0.016044:0.011118:0.004829:0.011067:0.011203:0.010399:0.010434:0.005798:0.005148:0.003421:0.011106:0.006636:0.004738:0.004738
Journal :@0.854051:0.704326:0.919322:0.704326:0.919322:0.690321:0.854051:0.690321:0.008244:0.011203:0.010399:0.005148:0.010434:0.011682:0.003421:0.004738
of Global Oncology. :@0.560000:0.718837:0.734704:0.718837:0.734704:0.704832:0.560000:0.704832:0.011203:0.005371:0.004738:0.014915:0.003421:0.011203:0.011665:0.011682:0.003421:0.004738:0.014864:0.010434:0.011067:0.011203:0.003421:0.011203:0.011511:0.009168:0.004738:0.004738
2018:4,1-6.:@0.734687:0.718837:0.820910:0.718837:0.820910:0.704832:0.734687:0.704832:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.004738:0.009476:0.005679:0.009476:0.004738